About the program

Target audience

This activity was intended for cardiologists and others caring for patients with acute coronary syndrome (ACS), who are status post stent or mechanical valve implantation, who are at risk of thromboembolism secondary to atrial fibrillation, or others in whom long-term antiplatelet or anticoagulant therapy is indicated.

Educational objectives

• Summarize data supporting the need for long-term anticoagulation in patients with paroxysmal or persistent atrial fibrillation
• Discuss reasons why patients with atrial fibrillation in whom long-term anticoagulation is indicated do not receive it and prospective means of addressing the “treatment gap”
• Describe current approaches to preventing late stent thrombosis, particularly in the case of drug eluting stents, and the potential role in this clinical context of antithrombotic agents under development
• Analyze data on the use of long-term antithrombotic therapy for secondary prevention following an episode of ACS.

Faculty info

CME

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Cincinnati and The Exeter Group.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Cincinnati designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credits commensurate with the extent of their participation.

The University of Cincinnati is committed to resolving all conflict of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturers.

The University of Cincinnati is committed to retaining only those speakers with financial interests that can be resolved and reconciled with the goals and educational integrity of the CME program.

Conflict of interest disclosure

The University of Cincinnati is committed to resolving all conflict of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be resolved and reconciled with the goals and educational integrity of the CME program.

In accordance with the ACCME Standards for Commercial Support the speakers for this course have been asked to disclose to participants the existence of any financial interest and/or relationship(s) (e.g., paid speaker, employee, paid consultant on a board and/or committee for a commercial company) that would potentially affect the objectivity of his/her presentation or whose products or services may be mentioned during their presentation. The following disclosures were made:

David L. Becker, MD

Planning committee member

President

The Exeter Group

New York, New York, United States

• No relationships

Eugene Braunwald, MD

Cochair, planning committee member, panelist

Distinguished Hersey Professor of Medicine

Harvard Medical School

Chairman, TIMI Study Group

Brigham and Women’s Hospital

Boston, Massachusetts, United States

• Advisory board/consultant: Bayer; CV Therapeutics; Cytokinetics; Daiichi Sankyo, Inc.; Genzyme; GlaxoSmithKline; Merck; Momenta Pharmaceuticals; Pfizer; sanofi–aventis; Schering–Plough
• Expert witness for DLA Piper (Law firm representing Pfizer)
• Grant recipient: AstraZeneca; Beckman Coulter; Bristol–Myers Squibb; CV Therapeutics; Daiichi Sankyo, Inc.; Eisai; Eli Lilly and Company; Genentech; Integrated Therapeutics; Johnson & Johnson; Merck; Novartis; Pfizer; Roche Diagnostics; sanofi–aventis; Schering–Plough Research Institute
• Speakers’ bureau: Eli Lilly and Company; Merck; sanofi–aventis; Schering–Plough

Robert M. Califf, MD

Cochair, planning committee member, panelist

Professor of Medicine

Vice Chancellor of Clinical Research

Director, Duke Translational Medicine Institute

Duke University Medical Center

Durham, North Carolina, United States

• Consultant: Amylin; AstraZeneca; Avalere Health; Bayer; Biogen Idec; Boehringer Ingelheim; Boston Scientific; Brandeis University; Bristol–Myers Squibb; Eli Lilly and Company; FivePrime; GlaxoSmithKline; Kowa Research Institute, Inc.; Medtronic; Merck; Nitrox, LLC; Novartis; sanofi–aventis; Schering–Plough; Scios; theheart.org/Conceptis; Vertex
• Speakers’ bureau: Kowa Research Institute, Inc.; Merck; Novartis; sanofi–aventis; Schering–Plough; Scios; theheart.org/Conceptis
• Grant support: Dr. Califf receives research support as director of the Duke Translational Medicine Institute from Novartis and Schering–Plough. Funding from Schering–Plough, payable to the Duke University Medical Center, is also provided for multi-center projects in which Dr. Califf serves as chair, cochair, executive committee member, or steering committee member. A portion of his salary as faculty member, representative of the percentage of effort on the project, has been supported by these funds during the past year.
• Shareholder: Nitrox, LLC

Lynn Fischer

Compliance

Program Director – Live Programs

Office of Continuing Medical Education

University of Cincinnati 

Cincinnati, Ohio, United States

• No relationships

C. Michael Gibson, MS, MD

Presenter, panelist

Associate Professor of Medicine

Harvard Medical School

Chief of Clinical Research

Division of Cardiovascular Medicine

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

• Consultant: Acusphere; Angel Medical Systems; Archemix; Bayer; Heartscape Technologies, Inc.; ICON Medical Imaging; Jim Moran Heart and Vascular Research Institute; Johnson & Johnson; Novartis; Portola; St. Jude Medical; Schering–Plough; The Medicines Company
• Grant recipient: Abbott; AstraZeneca; Baxter; Bayer; Cardica; FibroGen; FoldRx; Genentech; HeartScape Technologies; Johnson & Johnson; sanofi–aventis; Schering–Plough
• Receives royalties as a contributor to UpToDate
• Speakers’ bureau: Daiichi Sankyo, Inc.; Eli Lilly and Company; Schering–Plough
• Spouse/partner is a shareholder in Healthmarx

Kenneth W. Mahaffey, MD

Presenter, panelist

Director, Clinical Events Classification Group

Duke Clinical Research Institute

Associate Professor of Medicine

Duke University Medical Center

Durham, North Carolina, United States

• Consultant: Alexion Pharmaceuticals; Amgen; Bayer; Genentech; Johnson & Johnson; Novartis; Procter & Gamble; sanofi–aventis; Sanofi–Synthélabo; Schering–Plough Research Institute; Scios; The Medicines Company
• Grant recipient: Abbott Vascular; Alexion Pharmaceuticals; Amgen; AstraZeneca; Bayer; Bristol–Myers Squibb; CardioKinetix Inc.; Conor Medsystems; Cordis; Corgentech; Eli Lilly and Company; GE Healthcare; Genentech; Getz Pharma; Guidant Corporation (Boston Scientific); Johnson & Johnson; Medtronic; Novartis; Ortho Biotech; Procter & Gamble; sanofi–aventis; Schering–Plough Research Institute; Scios; Sicel Technologies, Inc.; The Medicines Company

Rick E. Ricer, MD

Content reviewer

Professor

Department of Family Medicine

University of Cincinnati College of Medicine

Cincinnati, Ohio, United States

• Advisory board: Primary Care Education Consortium

Freek W. A. Verheugt, MD

Presenter, panelist

Professor of Cardiology

HeartLung Center

Universitair Medisch Centrum St. Radboud, Nijmegen

Chairman, Department of Cardiology

Onze Lieve Vrouwe Gasthuis

Amsterdam, The Netherlands

• No relationships

Kay Weigand

Compliance

Program Director – Enduring Materials

Office of Continuing Medical Education

University of Cincinnati

Cincinnati, Ohio, United States

• No relationships

Disclaimer statement

The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

Off-label disclosure statement

Faculty members are required to inform the audience when they are discussing off-label/unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Studies cited during the program may have involved the speakers and/or received commercial support.

Presentations